Simple Summary When cancer returns after immune checkpoint inhibitor treatment given around curative surgery, clinicians often have little direct evidence to guide the next therapy. This review examines melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial carcinoma, and triple-negative breast cancer....
F. Petrelli, L. Dottorini, A. Ghidini et al.· Current Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.